Reporting owner · CIK 0001230724

Guggenhime Andrew

Visual SEC Form 4 history across 2 companies, 16 transactions and 5 filings.

PRESPRESIDENT AND CFOVaxcyte, Inc.
Open-market mix
Latest filingSep 02, 2026, 11:56 PM
Filings5Form 4 records
Buying$00 purchases
Selling$1.4M5 sales
Net value−$1.4MBuys minus sells
Companies23 securities
Most recentSep 02, 2026withholding

Open-market buy performance

90-day forward return on this insider's open-market purchases

90d forward
Forward return is not available yet

We compute this from each buy's stock performance 90 days after the transaction. The price history is still being populated for this insider's their open-market buys, so the average and median will appear here once the daily price refresh has covered the relevant trading days.

Monthly open-market activity

Reported purchase and sale transaction counts

Buys Sells
530-3-53Jan 252Feb 25Mar 25Aug 26Sep 26

Net value flow

Buys minus sells

Jan 25
−$692.1K
Feb 25
−$670.8K
Mar 25
$0
Aug 26
$0
Sep 26
$0

Transaction texture

Ownership and ticket size

Average P/S size$272.6K
Median P/S size$174.4K
Direct16
Indirect0
Sep 02, 2026withholding

Filing-only signals

Deterministic matches in this insider's history

Cluster Sellingpattern5Derivative Transactionfiling-context4Direct Ownershipfiling-context14Large Holdings Increaseholdings2Large Salesize1Repeat Sellerpattern410b5-1 Detectedfiling-context9

Latest Form 4 facts

Quick context from source filings

Latest transaction

sale at Vaxcyte, Inc. on Feb 18, 2025 valued at $153,766.

Review SEC filing
Latest buy

No open-market insider purchase is available.

Associated companies

Visual map of known reporting history

PCVXVaxcyte, Inc.15 transactions · latest Sep 02, 2026, 11:56 PMCRBUCaribou Biosciences, Inc.1 transactions · latest Feb 22, 2025, 01:14 AM
TickerInsiderRoleTypeSharesValueCodeSignals90d returnFiledTrans date
PCVXGUGGENHIME ANDREW
PRES
withholding1.43k-$8.81MF
Direct Ownership
0.0%09/0209/02
PCVXGUGGENHIME ANDREW
PRES
withholding1.27k-$7.73MF
Direct Ownership
0.0%09/0208/31
PCVXGUGGENHIME ANDREW
PRES
grant75.9k$0A
Derivative Transaction Direct Ownership Large Holdings Increase
—03/04/202502/27/2025
PCVXGUGGENHIME ANDREW
PRES
withholding3.80k-$27.4MF
Direct Ownership
—03/04/202503/03/2025
PCVXGUGGENHIME ANDREW
PRES
withholding1.27k-$9.27MF
Direct Ownership
—03/04/202502/28/2025
PCVXGUGGENHIME ANDREW
PRES
grant22.7k$0A
Direct Ownership
—03/04/202502/27/2025
CRBUGUGGENHIME ANDREW
DIR
grant40.5k$0A
Derivative Transaction Direct Ownership Large Holdings Increase
—02/22/202502/20/2025
PCVXGUGGENHIME ANDREW
PRES
exercise10b5-18.00k$0M
Derivative Transaction Direct Ownership 10b5-1 Detected
—02/19/202502/18/2025
PCVXGUGGENHIME ANDREW
PRES
sale10b5-11.81k-$15.3MS
Cluster Selling Direct Ownership Repeat Seller+1
—02/19/202502/18/2025
PCVXGUGGENHIME ANDREW
PRES
sale10b5-16.18k-$51.7MS
Cluster Selling Direct Ownership Large Sale+2
—02/19/202502/18/2025

Guggenhime Andrew Insider Activity FAQ

SEC Form 4 context

Who is Guggenhime Andrew?

Guggenhime Andrew is a reporting owner in SEC Form 4 filings with reporting owner CIK 0001230724.

Which companies has Guggenhime Andrew reported transactions for?

Vaxcyte, Inc., Caribou Biosciences, Inc.

When was Guggenhime Andrew's latest insider buy?

No open-market insider purchase is available for this period.

When was Guggenhime Andrew's latest insider sale?

sale at Vaxcyte, Inc. on Feb 18, 2025 valued at $153,766.

Where can I see the original SEC filings?

Each transaction row links directly to the source SEC filing so the reported Form 4 details can be reviewed.

Are performance metrics included?

This version does not calculate win rates, forward returns, benchmark-adjusted returns, or high-conviction scores.